Essential tool to
control bleeding*

• Stops bleeding fast in 90 seconds^#,1
• Conforms to irregular wound geometries and forms a mechanically stable clot^2,3
• Reduces blood transfusions and post operative bleeding⁴
• Proven 89% effective in heparinized patients within 10 minutes⁵

Please check our page often for updates on FLOSEAL in neurosurgery and our presence at the WFNS Congress.

*When control of bleeding by ligature or conventional procedures is ineffective or impractical

# median time to hemostasis in spinal surgery

View FLOSEAL Instructions for Use

See FLOSEAL's unique mechanism of action

FLOSEAL use in neurinoma excision case

FLOSEAL use in a spinal laminectomy

1. Renkens KL Jr., Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001;26:1645-1650. 2. Floseal VH S/D Hemostatic Matrix [instructions for use]. Zurich, Switzerland: Baxter Healthcare SA; 2009. 3. Oz MC et al. Floseal matrix: new generation topical hemostatic sealant. J Card Surg. 2003; 18: 486-493. 4. Nasso G et al. Prospective, randomized clinical trial of the Floseal matrix sealant in cardiac surgery. Annals of Thoracic Surgery. 2009; 88: 1520-1526. 5. Oz MC, Cosgrove DM, Badduke BR. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg. 2000;69:1376-1382.

Baxter and Floseal are trademarks of Baxter International Inc.
BS-BS-562 January 2011

©2011 Baxter Healthcare S.A.
P.O. Box
CH-8010 Zurich
Switzerland
www.floseal.com

Essential tool to
control bleeding*

• Stops bleeding fast in 90 seconds^#,1
• Conforms to irregular wound geometries and forms a mechanically stable clot^2,3
• Proven 89% effective in heparinized patients within 10 minutes⁴

The safety and effectiveness for use in neurosurgical procedures has not been established through randomized clinical studies.

*When control of bleeding by ligature or conventional procedures is ineffective or impractical

#median time to hemostasis in spinal surgery

For additional information on FLOSEAL, please select an abstract:
Gazzeri R, et al. Acta Neurochir (Wien). 2010.
Ellegala DB, et al. Neurosurgery. 2002.

Please check our page often for updates on FLOSEAL in neurosurgery and our presence at the WFNS Congress.

See the unique mechanism of action of
FLOSEAL Hemostatic Matrix

FLOSEAL Hemostatic Matrix use in
neurinoma excision case

FLOSEAL Hemostatic Matrix use
in a spinal laminectomy

FLOSEAL Hemostatic Matrix Indications
FLOSEAL is indicated in surgical procedures (other than ophthalmic) as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical.

Important Risk Information for FLOSEAL:
Do not use FLOSEAL in patients with known allergies to materials of bovine origin. Do not use FLOSEAL in the closure of skin incisions because it may interfere with the healing of the skin edges. FLOSEAL must not be injected into blood vessels, or allowed to enter blood vessels. Do not apply in the absence of active bleeding. Extensive intravascular clotting and even death may result. FLOSEAL is made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent. Excess FLOSEAL (material not incorporated in the hemostatic clot) should always be removed using gentle irrigation from the site of application. The maximum swell volume of approximately 20% is achieved within about 10 minutes.

RX only: For safe and proper use of this device, please refer to full device Instructions For Use.

View FLOSEAL IFU

1. Renkens KL Jr., Payner TD, Leipzig TJ, et al. A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal surgery. Spine. 2001;26:1645-1650. 2. FLOSEAL Hemostatic Matrix Instructions For Use. Hayward, CA: Baxter Healthcare Corporation; 0710217, May 2010. 3. Oz MC, Rondinone JF, Shargill NS. Floseal matrix: new generation topical hemostatic sealant. J Card Surg. 2003; 18: 486-493. 4. Oz MC, Cosgrove DM, Badduke BR. Controlled clinical trial of a novel hemostatic agent in cardiac surgery. Ann Thorac Surg. 2000;69:1376-1382.

Baxter and Floseal are registered trademarks of Baxter International Inc.